854
Participants
Start Date
May 31, 2007
Primary Completion Date
February 29, 2008
Study Completion Date
April 30, 2008
Morphine
20 mg IR; 4 - 6 hourly; Total 72 hours
CG5503 IR
50mg; 4 - 6 hourly; Total 72 hours
CG5503 IR
75mg; 4 -6 hourly; Total 72 hours
CG5503 IR
100mg, 4 - 6 hourly; Total 72 hours
Placebo
4 - 6 hourly; Total 72 hours
Site 13, Békéscsaba
Site 14, Debrecen
Site 15, Komárom
Site 12, Nyíregyháza
Site 16, Riga
Site 17, Riga
Site 18, Riga
Site 19, Riga
Site 27, Katowice
Site 23, Krakow
Site 24, Lodz
Site 66, Lodz
Site 22, Lublin
Site 25, Lublin
Site 26, Ruda Śląska
Site 20, Warsaw
Site 21, Warsaw
Site 28, Wroclaw
Site 33, Brasov
Site 78, Brasov
Site 29, Bucharest
Site 30, Bucharest
Site 31, Bucharest
Site 32, Bucharest
Site 34, Bucharest
Site 35, Bucharest
Site 36, Bucharest
Site 76, Bucharest
Site 75, Craiova
Site 61, Ploieşti
Site 71, Belgorod
Site 37, Moscow
Site 38, Moscow
Site 44, Moscow
Site 73, Moscow
Site 42, Saint Petersburg
Site 43, Saint Petersburg
Site 45, Belgrade
Site 47, Belgrade
Site 46, Kragujevac
Site 70, Novi Sad
Site 48, Banská Bystrica
Site 51, Bratislava
Site 52, Bratislava
Site 62, Košice
Site 50, Martin
Site 53, Maribor
Site 64, Donetsk
Site 55, Kiev
Site 56, Kiev
Site 58, Kiev
Site 67, Zaporizhya
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
Grünenthal GmbH
INDUSTRY